DJIA 16,373.25 110.69 0.68%
NASDAQ 4,067.00 32.84 0.81%
S&P 500 1,856.10 13.12 0.71%
market minute promo

ArQule, Inc.

NASDAQ: ARQL

1.71 -0.02 (-1.16%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ARQL $1.71 -1.16%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.76
Previous Close $1.73
Daily Range $1.69 - $1.77
52-Week Range $1.69 - $3.10
Market Cap $107.5M
P/E Ratio -4.44
Dividend (Yield) $0.00 (0.0%)
Volume 105,898
Average Daily Volume 350,241
Current FY EPS -$0.49

Sector

Healthcare

Industry

Drugs

ArQule, Inc. (ARQL) Description

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. Website: http://www.arqule.com/

News & Commentary

Stocks Hitting 52-Week Lows

ARQL: Insiders Vs. Shorts

ArQule's Loss Narrows in Q4 - Analyst Blog

Arqule's CEO Discusses Q4 2013 Results - Earnings Call Transcript

ArQule, Inc. Discusses Q4 2013 Results (Webcast)

Earnings Scheduled For March 5, 2014

A Close Look At ArQule

Data on ArQule's Tivantinib - Analyst Blog

Data on ArQule's Tivantinib - Analyst Blog

ArQule (ARQL) Jumps: Stock Rises 6.8% - Tale of the Tape

This Week in Biotech: Clinical Trials and Tribulations

The J.P. Morgan Healthcare Conference led to the release of five important clinical updates this week.

See More ARQL News...

ARQL's Top Competitors

ARQL $1.71 (-1.16%)
Current stock: ARQL
AMGN $115.39 (0.34%)
Current stock: AMGN
GILD $69.18 (1.48%)
Current stock: GILD
BIIB $292.12 (2.32%)
Current stock: BIIB